<DOC>
	<DOCNO>NCT01353781</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics preliminary anti-tumour activity ascend dos AZD5363 adaptable dose schedule Japanese patient advance solid malignancy .</brief_summary>
	<brief_title>Open Label Phase 1 Study Japan Patient With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Aged least 20 year Histological cytological confirmation solid malignant tumour , exclude lymphoma , refractory standard therapy standard therapy exist At least one lesion ( measurable and/or nonmeasurable ) accurately assess accord RECIST World Health Organisation ( WHO ) performance status 01 deterioration previous 2 week minimum life expectancy 12 week Patients willing remain hospital completion first cycle include cycle 0 , cycle 1 , cycle 2 Day1 ( cycle 1 Day 21 ) Clinically significant abnormality glucose metabolism define follow : Diagnosis diabetes mellitus type I II ( irrespective management ) Baseline fast glucose value â‰¥7 mmol/l ( 126mg/dL ) Glycosylated haemoglobin ( HbA1C ) &gt; 6.5 % Spinal cord compression brain metastasis unless asymptomatic , treat stable require steroid least 4 week prior start study treatment Inadequate bone marrow reserve organ function Any evidence severe uncontrolled systemic disease , include active bleeding diatheses , active infection With exception alopecia , unresolved toxicity prior therapy great CTCAE grade 1 time start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>AKT</keyword>
	<keyword>Ascending</keyword>
	<keyword>Japanese</keyword>
</DOC>